AstraZeneca, Europe’s largest drugmaker by market value, said on Monday it will pursue a direct listing of its ordinary shares on the New York Stock Exchange (NYSE) by February 2026, while stressing it will remain headquartered, tax resident, and primarily listed in the UK.
